
Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 166 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Gamida Cell
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GMDA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Gamida Cell stock price (NASDAQ: GMDA)
Use our graph to track the performance of GMDA stocks over time.Gamida Cell shares at a glance
Latest market close | $1.77 |
---|---|
52-week range | $1.79 - $6.84 |
50-day moving average | $2.38 |
200-day moving average | $3.17 |
Wall St. target price | $14.40 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.53 |
Buy Gamida Cell shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Gamida Cell stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gamida Cell price performance over time
Historical closes compared with the close of $1.77 from 2022-06-30
1 week (2022-06-22) | -7.33% |
---|---|
1 month (2022-06-01) | -18.06% |
3 months (2022-04-01) | -56.19% |
6 months (2021-12-31) | -30.31% |
1 year (2021-07-01) | -72.52% |
---|---|
2 years (2020-07-01) | -61.01% |
3 years (2019-07-01) | 5.09 |
5 years (2017-06-27) | N/A |
Gamida Cell financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -33.05% |
Return on equity TTM | -166.84% |
Profit margin | 0% |
Book value | $0.42 |
Market capitalisation | $118.1 million |
TTM: trailing 12 months
Gamida Cell share dividends
We're not expecting Gamida Cell to pay a dividend over the next 12 months.
Gamida Cell share price volatility
Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $1.79 up to $6.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 1.8195. This would suggest that Gamida Cell's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Gamida Cell overview
Gamida Cell Ltd. , a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel. .
Gamida Cell in the news

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
Frequently asked questions
What percentage of Gamida Cell is owned by insiders or institutions?Currently 30.16% of Gamida Cell shares are held by insiders and 29.513% by institutions. How many people work for Gamida Cell?
Latest data suggests 166 work at Gamida Cell. When does the fiscal year end for Gamida Cell?
Gamida Cell's fiscal year ends in December. Where is Gamida Cell based?
Gamida Cell's address is: 5 Nahum Heftsadie Street, Jerusalem, Israel, 91340 What is Gamida Cell's ISIN number?
Gamida Cell's international securities identification number is: IL0011552663 What is Gamida Cell's CUSIP number?
Gamida Cell's Committee on Uniform Securities Identification Procedures number is: M47364100
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert